Daiichi Sankyo Resubmits NDA for Iron Deficiency Anemia Treatment Injectafer to FDA

Daiichi Sankyo announced on October 13 that Luitpold Pharmaceuticals, its US subsidiary, has resubmitted an NDA for the iron deficiency anemia treatment Injectafer (ferric carboxymaltose injection) to the US FDA. This is the company’s second NDA submission for the drug...read more